SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 277 filers reported holding SAGE THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 1.64 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,934,952 | -45.0% | 94,021 | +25.7% | 0.00% | -50.0% |
| Q2 2023 | $3,517,519 | +322.6% | 74,809 | +277.1% | 0.00% | +300.0% |
| Q1 2023 | $832,444 | +8.7% | 19,839 | -1.2% | 0.00% | 0.0% |
| Q4 2022 | $766,156 | -2.6% | 20,088 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $786,646 | -69.5% | 20,088 | -74.8% | 0.00% | -85.7% |
| Q2 2022 | $2,579,000 | +18.8% | 79,824 | +21.8% | 0.01% | +75.0% |
| Q1 2022 | $2,170,000 | -23.2% | 65,541 | -1.3% | 0.00% | -20.0% |
| Q4 2021 | $2,825,000 | +669.8% | 66,414 | +701.1% | 0.01% | +400.0% |
| Q3 2021 | $367,000 | -21.6% | 8,290 | +0.5% | 0.00% | 0.0% |
| Q2 2021 | $468,000 | -22.3% | 8,246 | +2.5% | 0.00% | 0.0% |
| Q1 2021 | $602,000 | -16.6% | 8,046 | -3.5% | 0.00% | 0.0% |
| Q4 2020 | $722,000 | +33.2% | 8,341 | -5.9% | 0.00% | 0.0% |
| Q3 2020 | $542,000 | +41.1% | 8,864 | -4.0% | 0.00% | 0.0% |
| Q2 2020 | $384,000 | -26.9% | 9,229 | -49.5% | 0.00% | 0.0% |
| Q1 2020 | $525,000 | -61.6% | 18,266 | -3.6% | 0.00% | -66.7% |
| Q4 2019 | $1,368,000 | -61.2% | 18,947 | -24.6% | 0.00% | -62.5% |
| Q3 2019 | $3,526,000 | -22.6% | 25,133 | +1.0% | 0.01% | -20.0% |
| Q2 2019 | $4,556,000 | +10.0% | 24,882 | -4.4% | 0.01% | +11.1% |
| Q1 2019 | $4,141,000 | +56.0% | 26,035 | -6.1% | 0.01% | +28.6% |
| Q4 2018 | $2,655,000 | -33.3% | 27,713 | -1.7% | 0.01% | -12.5% |
| Q3 2018 | $3,981,000 | -14.4% | 28,185 | -5.1% | 0.01% | -20.0% |
| Q2 2018 | $4,648,000 | -90.7% | 29,695 | -90.4% | 0.01% | -90.6% |
| Q1 2018 | $49,764,000 | +1669.1% | 308,963 | +1709.0% | 0.11% | +1666.7% |
| Q4 2017 | $2,813,000 | +181.9% | 17,079 | +6.6% | 0.01% | +200.0% |
| Q3 2017 | $998,000 | -21.8% | 16,025 | 0.0% | 0.00% | -33.3% |
| Q2 2017 | $1,276,000 | +54.1% | 16,025 | +37.5% | 0.00% | +50.0% |
| Q1 2017 | $828,000 | -89.9% | 11,654 | -92.7% | 0.00% | -90.0% |
| Q4 2016 | $8,201,000 | -33.5% | 160,630 | -40.0% | 0.02% | -13.0% |
| Q3 2016 | $12,338,000 | +13.8% | 267,938 | -25.5% | 0.02% | -14.8% |
| Q2 2016 | $10,841,000 | +3215.3% | 359,813 | +6306.9% | 0.03% | +2600.0% |
| Q4 2015 | $327,000 | +37.4% | 5,616 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $238,000 | -50.8% | 5,616 | -15.4% | 0.00% | 0.0% |
| Q2 2015 | $484,000 | – | 6,636 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,966,688 | $120,204,000 | 10.81% |
| Integral Health Asset Management, LLC | 230,000 | $14,058,000 | 4.30% |
| Asymmetry Capital Management, L.P. | 102,462 | $6,262,000 | 4.02% |
| ACUTA CAPITAL PARTNERS, LLC | 225,000 | $13,752,000 | 3.74% |
| DAFNA Capital Management LLC | 158,306 | $9,676,000 | 3.14% |
| Bain Capital Life Sciences Investors, LLC | 499,100 | $30,505,000 | 2.84% |
| Boxer Capital, LLC | 1,094,000 | $66,865,000 | 2.31% |
| Palo Alto Investors LP | 590,200 | $36,073,000 | 1.98% |
| Logos Global Management LP | 250,000 | $15,280,000 | 1.96% |
| Bellevue Group AG | 1,579,504 | $96,539,000 | 1.33% |